-
Aug 2018
Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.
Clin ImmunolLord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, Kita M, Buckner JH -
Aug 2018
Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.
Pediatr DiabetesWeir GC, Ehlers MR, Harris KM, Kanaparthi S, Long SA, Phippard D, Weiner LJ, Jepson B, McNamara JG, Koulmanda M, Strom TB, ITN RETAIN Study Team. -
May 2018
Cytometry TOF identifies alveolar macrophage subtypes in acute respiratory distress syndrome.
JCI InsightMorrell ED, Wiedeman A, Long SA, Gharib SA, West TE, Skerrett SJ, Wurfel MM, Mikacenic C -
Sep 2017
Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
Cell ImmunolLong SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, Linsley PS, Nepom GT, Harris KM -
Aug 2017
Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state.
Clin ImmunolSchwedhelm K, Thorpe J, Murray SA, Gavin M, Speake C, Greenbaum C, Cerosaletti K, Buckner J, Long SA -
Nov 2016
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.
Sci ImmunolLong SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, Ehlers M, Herold KC, Nepom GT, Linsley PS -
Sep 2016
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.
Sci Transl MedHundhausen C, Roth A, Whalen E, Chen J, Schneider A, Long SA, Wei S, Rawlings R, Kinsman M, Evanko SP, Wight TN, Greenbaum CJ, Cerosaletti K, Buckner JH -
Nov 2015
Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Sci Transl MedBluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q -
Aug 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
J Clin InvestRigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR -
Apr 2015
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
J AutoimmunRosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D -
Dec 2013
Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients.
PLoS OneCerosaletti K, Schneider A, Schwedhelm K, Frank I, Tatum M, Wei S, Whalen E, Greenbaum CJ, Kita M, Buckner JH, Long SA -
Dec 2013
IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Clin ImmunolLong SA, Buckner JH, Greenbaum CJ -
Aug 2013
Intersection between genetic polymorphisms and immune deviation in type 1 diabetes.
Curr Opin Endocrinol Diabetes ObesLong SA, Buckner JH -
Jun 2013
Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.
Clin Exp ImmunolBollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ -
Jan 2013
In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling.
Sci Transl MedSchneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH
